Ipamorelin has real, direct pharmacokinetic data in humans testing nasal administration. This is a true point of differentiation from many other peptides discussed in this series. However, the same studies showed that nasal delivery is significantly less effective than injection. No equivalent human studies exist for oral capsule or tablet forms, which would encounter the same fundamental problem of digestive breakdown common to peptides generally.
Ipamorelin nasal spray
Unlike CJC-1295, which lacks a dedicated study on intranasal bioavailability, ipamorelin has in fact been directly tested via the intranasal route in human-like controlled pharmacokinetic studies. This makes it an area truly supported by evidence, rather than mere speculation. A pharmacokinetic study specifically comparing ipamorelin and other related peptide growth hormone stimulators showed that the bioavailability of ipamorelin following intranasal administration was approximately 20%. This means that roughly one-fifth of the administered dose reached the systemic circulation compared to injection [1].
This is a valid and useful data point. However, it is important to understand what it tells us. 20% represents a significantly reduced absorption rate compared to injection. The same studies showed that several structurally related compounds tested in these studies achieved higher intranasal bioavailability, closer to 50%. This suggests that ipamorelin’s chemical structure may make it comparatively less effective at crossing the nasal mucosa than some of its close chemical relatives [1].
This discovery demonstrates that nasal absorption of this general family of peptides is biologically real and measurable. However, it also implies that a nasal spray would be expected to deliver a significantly lower active dose into the bloodstream than an equivalent amount given by injection, based on these particular published studies.
It's worth noting that this pharmacokinetic study measured absorption into the bloodstream—not necessarily the resulting growth hormone response or any downstream clinical outcome from the nasal use specifically. So while the bioavailability number itself is well-documented, its practical significance for hormonal response after nasal spray use in a real product has not been separately confirmed by additional studies.
Ipamorelin oral capsules, tablets, and pills
Ipamorelin, as a peptide built from a five-amino-acid chain, would be expected to encounter the same fundamental barrier that affects peptide drugs as a category when swallowed. Digestive enzymes in the stomach and intestines, combined with the highly acidic stomach environment, generally break down peptides before they can be absorbed intact. Even fragments that survive encounter poor absorption through the intestinal wall due to their size and chemical properties [2]. This is a well-established, general principle of peptide pharmaceutical science, not a marketing-specific claim. No published pharmacokinetic study identified in these searches measured the oral bioavailability of ipamorelin specifically to confirm or refute how severely this barrier applies to it in practice.
As discussed in relation to CJC-1295 elsewhere in this series, achieving significant oral activity for this general class of compounds has historically required deliberate chemical re-engineering. A related, yet structurally distinct molecule, engineered specifically to survive digestion through modification of the core peptide backbone, achieved true oral bioavailability in animal testing. However, this involved a completely different, specially designed compound—not standard ipamorelin itself [3].
Based on general principles of peptide pharmacology and the absence of any dedicated oral bioavailability studies for unmodified ipamorelin, oral capsules, tablets, or pills containing standard ipamorelin peptide would not be expected to reliably deliver an effective, intact dose into systemic circulation. No clinical evidence supports oral formulations as an established, effective route for this specific compound.
Pens and injection devices for Ipamorelin
Regarding the needle size for injection, clinical studies of ipamorelin have used intravenous infusion, not standalone subcutaneous injection [4], [5]. This means no published study specifies the needle gauge or length used for standalone injection, as this is a practical, clinical detail relevant for at-home administration, rather than a scientific finding reported in outcome research articles. As general background applicable to subcutaneous peptide injections broadly, not specific to ipamorelin research, commonly used needles for this general purpose are typically short and thin. They are often in the range of 29 to 31 gauge and about 4 to 8 millimeters in length. This reflects standard practice to reach the subcutaneous fat tissue layer without going deeper into the muscle. This is a general injection convention derived from broader practices of peptide and insulin administration—not a validated recommendation specific to ipamorelin research or a pen device product.
Regarding pen devices specifically for ipamorelin, no reviewed studies identified in this series have evaluated such a device for this compound. As discussed for CJC-1295 elsewhere in this series, a „pen” is simply an alternate delivery mechanism for the same underlying peptide solution, not a distinct, separately studied formulation.
Limitations of current evidence
The intranasal bioavailability of ipamorelin, which is approximately 20%, is well documented by direct pharmacokinetic studies. This makes it one of the better-characterized routes of administration discussed anywhere in this series [1]. It is worth noting, however, that this figure describes absorption into the bloodstream, not a confirmed hormonal or clinical outcome specifically from intranasal spray products.
Oral capsule and tablet forms are not supported by any dedicated bioavailability study. General principles of peptide pharmacology suggest they would encounter significant degradation prior to absorption [2]. Needle size and injection device information reflect general practice across peptide administration rather than validated studies specific to ipamorelin.
Disclaimer
Ipamorelin is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body for any human use, in any delivery form, including nasal spray, oral capsules, tablets, or injections. It is not manufactured or marketed under the quality and safety oversight that applies to approved pharmaceuticals. The information in this article is based on published pharmacokinetic studies and general principles of peptide pharmacology, and does not establish that any specific delivery form is safe or effective for general use. This article is provided for general educational and informational purposes only, reflects the state of the published scientific literature at the time of writing, and does not constitute medical advice. It does not provide instructions for administration, and nothing within it should be interpreted as a recommendation to use, obtain, or administer ipamorelin in any form.
References
[1] Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976
Chen, G., Kang, W., Li, W., Chen, S., & Gao, Y. (2022). Oral delivery of protein and peptide drugs: From non-specific formulation approaches to intestinal cell targeting strategies. Theranostics, 12(3), 1419–1439. https://doi.org/10.7150/thno.61747
[3] Hansen, B. S., Raun, K., Nielsen, K. K., Johansen, P. B., Hansen, T. K., Peschke, B., Lau, J., Andersen, P. H., & Ankersen, M. (1999). Pharmacological characterization of a new oral GH secretagogue, NN703. European Journal of Endocrinology, 141(2), 180–189. https://doi.org/10.1530/eje.0.1410180
[4] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[5] Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8